Wall Street Analysts Think Amneal (AMRX) Could Surge 43.82%: Read This Before Placing a BetZacks Investment Research • 07/29/25
Is Amneal Pharmaceuticals (AMRX) Outperforming Other Medical Stocks This Year?Zacks Investment Research • 07/28/25
Amneal Announces Proposed Refinancing of Existing Credit Agreement, including Private Offering of Senior Secured Notes Due 2032GlobeNewsWire • 07/21/25
Knight Therapeutics Announces Filing of New Drug Submission for CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in CanadaGlobeNewsWire • 07/18/25
Amneal Highlights Positive Topline Results from Confirmatory Clinical Study of Biosimilar Candidate to XOLAIR(R) (omalizumab), Developed by Kashiv BioSciencesGlobeNewsWire • 06/25/25
Amneal Receives U.S. FDA Approval for Prednisolone Acetate Ophthalmic SuspensionGlobeNewsWire • 06/12/25
Wall Street Analysts Believe Amneal (AMRX) Could Rally 54.36%: Here's is How to TradeZacks Investment Research • 06/04/25
Amneal Receives U.S. FDA Approval for Brekiya® (dihydroergotamine mesylate) injection for the Acute Treatment of Migraine and Cluster Headaches in AdultsGlobeNewsWire • 05/15/25
Does Amneal (AMRX) Have the Potential to Rally 54.16% as Wall Street Analysts Expect?Zacks Investment Research • 05/09/25
Amneal and Apiject to Expand Sterile and Blow-Fill-Seal (BFS) Capabilities for Advanced Pharmaceutical Manufacturing in the U.S.GlobeNewsWire • 05/08/25
Amneal Donates $1.5 Million to Support Patients During Parkinson's Awareness MonthBusiness Wire • 04/11/25
Amneal Announces New Data from Phase 3 Study Showing Significant Improvements in Sleep Quality with CREXONT® (Carbidopa and Levodopa) Extended-Release Capsules in Parkinson's DiseaseBusiness Wire • 04/07/25
Amneal Announces Expanded Coverage for CREXONT® (Carbidopa and Levodopa) to Enhance Access for Parkinson's Disease Patients in the U.S.Business Wire • 04/03/25